Indian Council for Medical Research (ICMR) has approved Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Kerala, to develop a protocol for convalescent plasma therapy trial to treat severely ill COVID-19 patients.
Plasma therapy uses the antibodies present in the blood plasma of COVID-19 recovered individuals to treat severely-ill COVID-19 patients. This has been effectively used in some severe cases abroad. SCTIMST will develop this treatment on a trial basis here, said a senior Indian Council of Medical Research (ICMR) official.
Convalescent plasma (CP) transfusion is classic adaptive immunotherapy that had been tried previously in the prevention and treatment of SARS, MERS, and 2009 H1N1 pandemic. The researchers would now explore the feasibility of CP transfusion to rescue severe patients
since no specific antiviral agents currently available for treatment of COVID-19. In CP therapy, the patients will be given plasma from patients recovered from SARS-CoV-2 through transfusions.